Europe Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombin

Europe Biopharmaceuticals Market Forecast to 2028-Regional Analysis- by Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)


The Europe biopharmaceuticals market was valued at US$ 107.57 billion in 2022 and is expected to reach US$ 227.22 billion by 2028. It is estimated to register a CAGR of 13.3% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drive Europe Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceuticals companies to redirect resources to other important areas. Many biopharmaceuticals’ companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increase dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron for advancing the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. In November 2021, Abenza Limited, a biologics research partner, announced a collaboration with BiVictriX Therapeutics to manufacture the BiVictriX ADCs. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the Europe biopharmaceuticals market in the coming years.

Europe Biopharmaceuticals Market Overview

The Europe biopharmaceuticals market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Europe biopharmaceuticals market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, growing cancer incidences, and launch of innovative products by market players in the region. The emerging biopharmaceuticals industry in Europe results from an evolution of the traditional pharmaceutical industry. The industry has considered the recent advances in biotechnology developed on living cells and molecules that have resulted from key innovations in healthcare. The most specific area of biopharmaceuticals product development includes vaccines, blood components, hormones, antibodies, cell-based therapies, stem cells, gene therapy, or enzymes. In May 2019, the European Union approved 59 biosimilars, and many have been successfully commercialized. Most regions with strong clusters in the biopharmaceuticals industry are Belgium, Sweden, Germany, Norway, the UK, France, Italy, and Spain. Belgium can be identified as an important player in terms of biopharmaceuticals. Major Belgian pharmaceutical companies include Janssen Pharmaceutica, Solvay, UCB (Union Chimique Belge), GMED Healthcare, and subsidiaries such as BASF Antwerpen and GlaxoSmithKline Biologicals. The regions specializing in biopharmaceuticals perform well in many economic indicators due to high labor productivity. These regions also have numerous product and process, marketing, and organizational innovators, and they also score with high-tech employment. The growing population and chronic diseases are driving the market growth. Hence, based on the above factors, the Europe biopharmaceuticals market is expected to grow during the forecast period.

Exhibit: Europe Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Million)

Europe Biopharmaceuticals Market Segmentation

The Europe biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the Europe biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the Europe biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the Europe biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the Europe biopharmaceuticals market.

Based on country, the Europe biopharmaceuticals market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, Germany held the largest share of the Europe biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are among the leading companies operating in the Europe biopharmaceuticals market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe biopharmaceutical market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution


1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Biopharmaceuticals Market - by Product Type
1.3.2 Europe Biopharmaceuticals Market - by Application
1.3.3 Europe Biopharmaceuticals Market - by Country
2. Europe Biopharmaceuticals Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Biopharmaceuticals Market - Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. Europe Biopharmaceuticals Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Application in Cancer Therapeutics
5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
5.3.1 Accelerated Clinical Trials
5.4 Future Trends
5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis
6. Biopharmaceuticals Market - Europe Analysis
6.1 Europe Biopharmaceuticals Market Revenue Forecast and Analysis
7. Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type
7.1 Overview
7.2 Europe Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
7.3.1 Overview
7.3.2 Monoclonal Antibodies: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
7.4.1 Overview
7.4.2 Recombinant Vaccines: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Cancer Vaccine
7.4.2.1.1 Overview
7.4.2.1.2 Cancer Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Malaria Vaccine
7.4.2.2.1 Overview
7.4.2.2.2 Malaria Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Ebola Vaccine
7.4.2.3.1 Overview
7.4.2.3.2 Ebola Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Hepatitis-B Vaccine
7.4.2.4.1 Overview
7.4.2.4.2 Hepatitis-B Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.5 Tetanus Vaccine
7.4.2.5.1 Overview
7.4.2.5.2 Tetanus Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.6 Diphtheria Vaccine
7.4.2.6.1 Overview
7.4.2.6.2 Diphtheria Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.7 Cholera Vaccine
7.4.2.7.1 Overview
7.4.2.7.2 Cholera Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.8 Others
7.4.2.8.1 Overview
7.4.2.8.2 Others: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
7.5.1 Overview
7.5.2 Conventional Vaccines: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Polio Vaccine
7.5.2.1.1 Overview
7.5.2.1.2 Polio Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Pox Vaccine
7.5.2.2.1 Overview
7.5.2.2.2 Pox Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Other Conventional Vaccine
7.5.2.3.1 Overview
7.5.2.3.2 Other Conventional Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
7.6.1 Overview
7.6.2 Recombinant Growth Factors: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 Erythropoietin
7.6.2.1.1 Overview
7.6.2.1.2 Erythropoietin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Granulocyte Colony Stimulating Factor
7.6.2.2.1 Overview
7.6.2.2.2 Granulocyte Colony Stimulating Factor: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
7.7.1 Overview
7.7.2 Purified Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Leukemia Inhibitory Factor (LIF)
7.7.2.1.1 Overview
7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 P53 Protein
7.7.2.2.1 Overview
7.7.2.2.2 P53 Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.3 P38 Protein
7.7.2.3.1 Overview
7.7.2.3.2 P38 Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.4 Other Purified Proteins
7.7.2.4.1 Overview
7.7.2.4.2 Other Purified Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
7.8.1 Overview
7.8.2 Recombinant Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.1 Serum Albumin
7.8.2.1.1 Overview
7.8.2.1.2 Serum Albumin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.2 Amyloid Protein
7.8.2.2.1 Overview
7.8.2.2.2 Amyloid Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.3 Defensin
7.8.2.3.1 Overview
7.8.2.3.2 Defensin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8.2.4 Transferrin
7.8.2.4.1 Overview
7.8.2.4.2 Transferrin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
7.9.1 Overview
7.9.2 Recombinant Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.1 Recombinant Human Growth Hormones
7.9.2.1.1 Overview
7.9.2.1.2 Recombinant Human Growth Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.2 Recombinant Insulin
7.9.2.2.1 Overview
7.9.2.2.2 Recombinant Insulin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9.2.3 Other Recombinant Hormones
7.9.2.3.1 Overview
7.9.2.3.2 Other Recombinant Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
7.10.1 Overview
7.10.2 Recombinant Enzymes: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.1 Enterokinase
7.10.2.1.1 Overview
7.10.2.1.2 Enterokinase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.2 Cyclase
7.10.2.2.1 Overview
7.10.2.2.2 Cyclase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.3 Caspase
7.10.2.3.1 Overview
7.10.2.3.2 Caspase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10.2.4 Cathepsin
7.10.2.4.1 Overview
7.10.2.4.2 Cathepsin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
7.11.1 Overview
7.11.2 Cell and Gene Therapies: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.1 Allogenic Products
7.11.2.1.1 Overview
7.11.2.1.2 Allogenic Products: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.2 Autologous Products
7.11.2.2.1 Overview
7.11.2.2.2 Autologous Products: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11.2.3 Acellular Products
7.11.2.3.1 Overview
7.11.2.3.2 Acellular Products: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
7.12.1 Overview
7.12.2 Cytokines/Interferon/Interleukins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
7.13.1 Overview
7.13.2 Others (mRNA Based Therapeutics, etc.): Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8. Europe Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application
8.1 Overview
8.2 Europe Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
8.4.1 Overview
8.4.2 Inflammatory and Infectious Diseases: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
8.5.1 Overview
8.5.2 Autoimmune Disorders: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolic Disorders: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
8.7.1 Overview
8.7.2 Hormonal Disorders and Growth Failure: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
8.8.1 Overview
8.8.2 Cardiovascular Diseases: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
8.9.1 Overview
8.9.2 Neurological Diseases: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
8.10.1 Overview
8.10.2 Other Therapeutic Applications: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9. Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis
9.1 Overview
9.1.1 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
9.1.1.1 United Kingdom: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.2 Germany: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.2.2 Germany: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.3 France: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.3.1 France: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.3.2 France: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.4 Italy: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.4.2 Italy: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.5 Spain: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.5.2 Spain: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.1.1.6 Rest of Europe: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
9.1.1.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
9.1.1.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
9.1.1.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
9.1.1.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
9.1.1.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
9.1.1.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
9.1.1.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
9.1.1.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
9.1.1.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
9.1.1.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
10. Europe Biopharmaceuticals Market - Industry Landscape
10.1 Overview
10.2 Organic Growth Strategies
10.2.1 Overview
10.3 Inorganic Growth Strategies
10.3.1 Overview
11. Company Profiles
11.1 Amgen Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 AbbVie Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Eli Lilly and Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Johnson & Johnson
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Boehringer Ingelheim International GmbH
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Thermo Fisher Scientific Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 AGC Biologics AS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Lonza Group AG
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 WuXi Biologics Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Table 2. United Kingdom Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 3. United Kingdom Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 4. United Kingdom Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 5. United Kingdom Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 6. United Kingdom Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 7. United Kingdom Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 8. United Kingdom Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 9. United Kingdom Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 10. United Kingdom Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 11. United Kingdom Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 12. Germany Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 13. Germany Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 14. Germany Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 15. Germany Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 16. Germany Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 17. Germany Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 18. Germany Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 19. Germany Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 20. Germany Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 21. Germany Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 22. France Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 23. France Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 24. France Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 25. France Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 26. France Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 27. France Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 28. France Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 29. France Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 30. France Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 31. France Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 32. Italy Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 33. Italy Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 34. Italy Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 35. Italy Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 36. Italy Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 37. Italy Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 38. Italy Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 39. Italy Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 40. Italy Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 41. Italy Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 42. Spain Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 43. Spain Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 44. Spain Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 45. Spain Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 46. Spain Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 47. Spain Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 48. Spain Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 49. Spain Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 50. Spain Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 51. Spain Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 52. Rest of Europe Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 53. Rest of Europe Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 54. Rest of Europe Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 55. Rest of Europe Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 56. Rest of Europe Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 57. Rest of Europe Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 58. Rest of Europe Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 59. Rest of Europe Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 60. Rest of Europe Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 62. Recent Organic Growth Strategies in Biopharmaceuticals Market
Table 63. Recent Inorganic Growth Strategies in the Europe biopharmaceuticals market
Table 64. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Biopharmaceuticals Market Segmentation
Figure 2. Europe Biopharmaceuticals Market, by Country
Figure 3. Europe Biopharmaceuticals Market Overview
Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in Europe Biopharmaceuticals Market
Figure 5. UK Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Europe Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
Figure 10. Europe Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 11. Monoclonal Antibodies: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 12. Recombinant Vaccines: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 13. Cancer Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 14. Malaria Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 15. Ebola Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 16. Hepatitis-B Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. Tetanus Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 18. Diphtheria Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 19. Cholera Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. Others: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Conventional Vaccines: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Polio Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pox Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Other Conventional Vaccine: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Recombinant Growth Factors: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Erythropoietin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Granulocyte Colony Stimulating Factor: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Purified Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Leukemia Inhibitory Factor (LIF): Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. P53 Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. P38 Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Other Purified Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Recombinant Proteins: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Serum Albumin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Amyloid Protein: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Defensin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Transferrin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. Recombinant Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Recombinant Human Growth Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Recombinant Insulin: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Other Recombinant Hormones: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Recombinant Enzymes: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Enterokinase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Cyclase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Caspase: Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings